DOCSLIB.ORG

Metabolite Standards Detected by UHPLC-HRMS

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Metabolite Standards Detected by UHPLC-HRMS Metabolite standards detected by UHPLC-HRMS #ID NAME 1 - 1,2-DIDECANOYL-SN-GLYCERO-3-PHOSPHOCHOLINE 2 - 10-HYDROXYDECANOATE 3 - 1-HYDROXY-2-NAPHTHOATE 4 - 2,4-DIHYDROXYPTERIDINE 5 - 2,6-DIHYDROXYPYRIDINE 6 - 2-Sulfoaniline 7 - 3-AMINO-4-HYDROXYBENZOATE 8 - 3-AMINO-5-HYDROXYBENZOATE 9 - 3-Hydroxyphenyl acetate 10 - 3-METHYL-2-OXINDOLE 11 - 3-NITRO-L-TYROSINE 12 - 4-QUINOLINECARBOXYLATE 13 - 4-QUINOLINECARBOXYLIC ACID 14 - ANILINE-2-SULFONATE (2-SULFOANILINE) 15 - BIS(2-ETHYLHEXYL)PHTHALATE 16 - CORTISOL 21-ACETATE 17 - delta-Valerolactone 18 - DEOXYCORTICOSTERONE ACETATE 19 - DIDECANOYL-GLYCEROPHOSPHOCHOLINE 20 - D-MANNOSAMINE 21 - ETHYL 3-INDOLEACETATE 22 - GALACTOSAMINE 23 - GLUCOSAMINATE 24 - Hydrocortisone acetate 25 - Hydrocortisone acetate (CORTISOL 21-ACETATE) 26- LUMICHROME 27 - Methyl vallinic acid 28 - N6-(DELTA2-ISOPENTENYL)-ADENINE 29 - N-ACETYLPROLINE 30 - N-METHYLGLUTAMATE 31- PALATINOSE 32 - S-HEXYL-GLUTATHIONE 33 - SN-GLYCERO-3-PHOSPHOCHOLINE 34 - URACIL 5-CARBOXYLATE 35 HMDB0000001 1-METHYL-L-HISTIDINE 36 HMDB0000012 DEOXYURIDINE 37 HMDB0000014 DEOXYCYTIDINE 38 HMDB0000015 CORTEXOLONE 39 HMDB0000017 4-pyridoxic acid 40 HMDB0000020 p-hydroxyphenylacetic acid 41 HMDB0000022 3-METHOXYTYRAMINE 42 HMDB0000026 ureidopropionic acid 43 HMDB0000030 BIOTIN 44 HMDB0000033 CARNOSINE 45 HMDB0000034 ADENINE 46 HMDB0000036 Taurocholic acid (TCA) 47 HMDB0000038 DIHYDROBIOPTERIN 48 HMDB0000043 BETAINE 49 HMDB0000045 ADENOSINE MONOPHOSPHATE (AMP) Inselspital Printed on 30.05.2018 University Institute of Clinical Chemistry Page 1/9 Bern, Switzerland Metabolite standards detected by UHPLC-HRMS #ID NAME 50 HMDB0000048 MELIBIOSE 51 HMDB0000050 ADENOSINE 52 HMDB0000052 Argininosuccinic acid 53 HMDB0000053 Androstenedione 54 HMDB0000058 CYCLIC AMP 55 HMDB0000062 L-CARNITINE 56 HMDB0000063 CORTISOL 57 HMDB0000064 CREATINE 58 HMDB0000068 EPINEPHRINE 59 HMDB0000070 pipecolic acid 60 HMDB0000073 DOPAMINE 61 HMDB0000076 DIHYDROURACIL 62 HMDB0000085 DEOXYGUANOSINE 63 HMDB0000089 CYTIDINE 64 HMDB0000094 Citric acid 65 HMDB0000095 CYTIDINE MONOPHOSPHATE 66 HMDB0000099 L-CYSTATHIONINE 67 HMDB0000101 DEOXYADENOSINE 68 HMDB0000107 GALACTITOL 69 HMDB0000112 gamma-aminobutyric acid 70 HMDB0000118 Homovanillic acid 71 HMDB0000121 Folic acid 72 HMDB0000122 D-Glucose 73 HMDB0000125 GLUTATHIONE 74 HMDB0000126 GLYCEROL 3-PHOSPHATE 75 HMDB0000127 D-Glucuronic acid 76 HMDB0000128 Guanidoacetic acid 77 HMDB0000130 homogentisic acid 78 HMDB0000132 GUANINE 79 HMDB0000133 GUANOSINE 80 HMDB0000134 fumaric acid 81 HMDB0000138 Glycocholic acid (GCA) 82 HMDB0000143 D-GALACTOSE 83 HMDB0000148 L-Glutamic acid 84 HMDB0000150 Gluconolactone 85 HMDB0000151 beta-estradiol 86 HMDB0000152 Gentisic acid 87 HMDB0000156 L-Malic acid 88 HMDB0000157 Hypoxanthine 89 HMDB0000158 L-TYROSINE 90 HMDB0000159 L-PHENYLALANINE 91 HMDB0000162 L-Proline 92 HMDB0000163 D-MALTOSE 93 HMDB0000167 L-THREONINE 94 HMDB0000168 L-ASPARAGINE 95 HMDB0000169 D-Mannose 96 HMDB0000172 L-ISOLEUCINE 97 HMDB0000175 Inosinic acid 98 HMDB0000176 maleic acid Inselspital Printed on 30.05.2018 University Institute of Clinical Chemistry Page 2/9 Bern, Switzerland Metabolite standards detected by UHPLC-HRMS #ID NAME 99 HMDB0000177 L-HISTIDINE 100 HMDB0000181 L-DOPA 101 HMDB0000182 L-Lysine 102 HMDB0000186 Alpha-LACTOSE 103 HMDB0000191 L-Aspartic acid 104 HMDB0000192 L-CYSTINE 105 HMDB0000194 ANSERINE 106 HMDB0000195 INOSINE 107 HMDB0000197 Indoleacetic acid 108 HMDB0000201 L-Acetylcarnitine (C2) 109 HMDB0000202 methylmalonic acid 110 HMDB0000207 Oleic acid 111 HMDB0000208 Oxoglutaric acid 112 HMDB0000210 PANTOTHENIC ACID 113 HMDB0000211 MYOINOSITOL 114 HMDB0000212 N-ACETYLGALACTOSAMINE 115 HMDB0000215 N-ACETYL-D-GLUCOSAMINE 116 HMDB0000216 norepinephrine (NORADRENALINE) 117 HMDB0000220 Palmitic acid 118 HMDB0000222 L-PALMITOYLCARNITINE (C16) 119 HMDB0000226 orotic acid 120 HMDB0000227 mevalonic acid 121 HMDB0000229 Nicotinamide ribotide 122 HMDB0000230 N-Acetylneuraminic acid 123 HMDB0000234 Testosterone 124 HMDB0000239 PYRIDOXINE 125 HMDB0000244 RIBOFLAVIN 126 HMDB0000247 SORBITOL 127 HMDB0000248 THYROXINE 128 HMDB0000251 TAURINE 129 HMDB0000252 Sphingosine 130 HMDB0000254 succinic acid 131 HMDB0000258 SUCROSE 132 HMDB0000262 Thymine 133 HMDB0000265 LIOTHYRONINE 134 HMDB0000267 pyroglutamic acid 135 HMDB0000269 SPHINGANINE 136 HMDB0000271 SARCOSINE 137 HMDB0000273 THYMIDINE 138 HMDB0000283 D-RIBOSE 139 HMDB0000286 URIDINE DIPHOSPHATE GLUCOSE 140 HMDB0000288 URIDINE 5'-MONOPHOSPHATE 141 HMDB0000289 Uric acid 142 HMDB0000290 URIDINE DIPHOSPHATE-N-ACETYLGLUCOSAMINE 143 HMDB0000291 Vanillylmandelic acid 144 HMDB0000292 XANTHINE 145 HMDB0000296 URIDINE 146 HMDB0000299 XANTHOSINE 147 HMDB0000300 URACIL Inselspital Printed on 30.05.2018 University Institute of Clinical Chemistry Page 3/9 Bern, Switzerland Metabolite standards detected by UHPLC-HRMS #ID NAME 148 HMDB0000301 urocanic acid 149 HMDB0000303 TRYPTAMINE 150 HMDB0000304 URIDINE DIPHOSPHATE-N-ACETYLGALACTOSAMINE 151 HMDB0000306 TYRAMINE 152 HMDB0000310 Methylacetoacetic acid 153 HMDB0000318 3,4-DIHYDROXYPHENYLGLYCOL 154 HMDB0000355 3-Hydroxymethylglutaric acid 155 HMDB0000397 2-Pyrocatechuic acid 156 HMDB0000418 18-Hydroxycortisol 157 HMDB0000422 2-METHYLGLUTARIC ACID 158 HMDB0000426 Citramalic acid 159 HMDB0000446 N-ALPHA-ACETYLLYSINE 160 HMDB0000448 adipic acid 161 HMDB0000450 5-HYDROXYLYSINE 162 HMDB0000462 ALLANTOIN 163 HMDB0000469 5-HYDROXYMETHYLURACIL 164 HMDB0000472 5-Hydroxy-L-tryptophan 165 HMDB0000479 3-Methyl-L-histidine 166 HMDB0000482 Caprylic acid 167 HMDB0000491 3-methyl-2-oxovaleric acid 168 HMDB0000497 5,6-Dihydrouridine 169 HMDB0000500 4-hydroxybenzoic acid 170 HMDB0000508 RIBITOL 171 HMDB0000510 aminoadipic acid 172 HMDB0000512 N-Acetyl-L-phenylalanine 173 HMDB0000517 L-ARGININE 174 HMDB0000518 chenodeoxycholic acid 175 HMDB0000526 5a-Tetrahydrocortisol 176 HMDB0000528 4,5-Dihydroorotic acid 177 HMDB0000532 Acetylglycine 178 HMDB0000562 CREATININE 179 HMDB0000573 Elaidic acid 180 HMDB0000575 DL-Homocystine 181 HMDB0000582 3,5-Diiodothyronine 182 HMDB0000592 GLUCOSAMINE 6-SULFATE 183 HMDB0000593 PC(18:1/18:1) 184 HMDB0000618 D-Ribulose 5-phosphate 185 HMDB0000619 Cholic acid (CA) 186 HMDB0000625 gluconic acid 187 HMDB0000626 deoxycholic acid 188 HMDB0000630 Cytosine 189 HMDB0000631 Deoxycholic acid glycine conjugate (GDCA) 190 HMDB0000634 Citraconic acid 191 HMDB0000637 Chenodeoxycholic acid glycine conjugate (GCDCA) 192 HMDB0000639 Galactaric acid 193 HMDB0000641 L-Glutamine 194 HMDB0000645 GALACTOSE 1-PHOSPHATE 195 HMDB0000651 Decanoylcarnitine (C10) 196 HMDB0000660 D-Fructose Inselspital Printed on 30.05.2018 University Institute of Clinical Chemistry Page 4/9 Bern, Switzerland Metabolite standards detected by UHPLC-HRMS #ID NAME 197 HMDB0000661 glutaric acid 198 HMDB0000669 Ortho-Hydroxyphenylacetic acid 199 HMDB0000673 Linoleic acid 200 HMDB0000682 INDOXYL SULFATE 201 HMDB0000684 L-Kynurenine 202 HMDB0000687 L-Leucine 203 HMDB0000688 Isovalerylcarnitine (C5) 204 HMDB0000694 L-2-Hydroxyglutaric acid 205 HMDB0000696 L-Methionine 206 HMDB0000698 Lithocholic acid glycine conjugate (GLCA) 207 HMDB0000703 mandelic acid 208 HMDB0000705 Hexanoylcarnitine (C6) 209 HMDB0000707 4-hydroxyphenylpyruvic acid 210 HMDB0000708 Glycoursodeoxycholic acid (GUDCA) 211 HMDB0000714 hippuric acid 212 HMDB0000715 kynurenic acid 213 HMDB0000716 L-pipecolic acid 214 HMDB0000719 L-Homoserine 215 HMDB0000722 Lithocholyltaurine (TLCA) 216 HMDB0000725 4-Hydroxyproline 217 HMDB0000733 Hyodeoxycholic acid 218 HMDB0000742 HOMOCYSTEINE 219 HMDB0000752 Methylglutaric acid 220 HMDB0000755 Hydroxyphenyllactic acid 221 HMDB0000761 Lithocholic acid (LCA) 222 HMDB0000763 5-Hydroxyindoleacetic acid 223 HMDB0000765 MANNITOL 224 HMDB0000766 N-Acetyl-L-Alanine 225 HMDB0000774 PREGNENOLONE SULFATE 226 HMDB0000784 azelaic acid 227 HMDB0000791 L-Octanoylcarnitine (C8) 228 HMDB0000792 sebacic acid 229 HMDB0000802 PTERIN 230 HMDB0000805 Pyrrolidonecarboxylic acid 231 HMDB0000806 myristic acid 232 HMDB0000812 n-acetyl-l-aspartic acid 233 HMDB0000819 NORMETANEPHRINE 234 HMDB0000824 Propionylcarnitine (C3) 235 HMDB0000827 Stearic acid 236 HMDB0000842 quinaldic acid 237 HMDB0000848 Stearoylcarnitine (C18) 238 HMDB0000857 Pimelic acid 239 HMDB0000858 monomethyl glutaric acid 240 HMDB0000870 HISTAMINE 241 HMDB0000873 4-METHYLCATECHOL 242 HMDB0000874 Tauroursodeoxycholic acid (TUDCA) 243 HMDB0000875 TRIGONELLINE 244 HMDB0000881 Xanthurenic acid 245 HMDB0000883 L-VALINE Inselspital Printed on 30.05.2018 University Institute of Clinical Chemistry Page 5/9 Bern, Switzerland Metabolite standards detected by UHPLC-HRMS #ID NAME 246 HMDB0000893 suberic acid 247 HMDB0000896 Taurodeoxycholic acid (TDCA) 248 HMDB0000902 NAD 249 HMDB0000904 Citrulline 250 HMDB0000905 DEOXYADENOSINE MONOPHOSPHATE 251 HMDB0000929 L-TRYPTOPHAN 252 HMDB0000930 TRANS-CINNAMic acid 253 HMDB0000939 S-ADENOSYLHOMOCYSTEINE 254 HMDB0000946 Ursodesoxycholic acid 255 HMDB0000951 Taurochenodesoxycholic acid (TCDCA) 256 HMDB0000954 trans-ferulic acid 257 HMDB0000962 LIPOAMIDE 258 HMDB0000975 TREHALOSE 259 HMDB0001015 N-FORMYL-L-METHIONINE 260 HMDB0001065 2-Hydroxyphenethylamine 261 HMDB0001072 COENZYME Q10 262 HMDB0001078 MANNOSE 6-PHOSPHATE 263 HMDB0001123 2-Aminobenzoic acid 264 HMDB0001129 N-ACETYLMANNOSAMINE 265 HMDB0001138 n-acetylglutamic acid 266 HMDB0001149 5-aminolevulinic acid 267 HMDB0001151 ALLOSE 268 HMDB0001160 tricosanoic acid 269 HMDB0001161 4-Trimethylammoniobutanoic acid 270 HMDB0001173 5'-Methylthioadenosine 271 HMDB0001178 ADENOSINE DIPHOSPHATE RIBOSE 272 HMDB0001186 N1-ACETYLSPERMINE 273 HMDB0001190
Load more

Recommended publications
  • Amplification of Oxidative Stress by a Dual Stimuli-Responsive Hybrid Drug
    ARTICLE Received 11 Jul 2014 | Accepted 12 Mar 2015 | Published 20 Apr 2015 DOI: 10.1038/ncomms7907 Amplification of oxidative stress by a dual stimuli-responsive hybrid drug enhances cancer cell death Joungyoun Noh1, Byeongsu Kwon2, Eunji Han2, Minhyung Park2, Wonseok Yang2, Wooram Cho2, Wooyoung Yoo2, Gilson Khang1,2 & Dongwon Lee1,2 Cancer cells, compared with normal cells, are under oxidative stress associated with the increased generation of reactive oxygen species (ROS) including H2O2 and are also susceptible to further ROS insults. Cancer cells adapt to oxidative stress by upregulating antioxidant systems such as glutathione to counteract the damaging effects of ROS. Therefore, the elevation of oxidative stress preferentially in cancer cells by depleting glutathione or generating ROS is a logical therapeutic strategy for the development of anticancer drugs. Here we report a dual stimuli-responsive hybrid anticancer drug QCA, which can be activated by H2O2 and acidic pH to release glutathione-scavenging quinone methide and ROS-generating cinnamaldehyde, respectively, in cancer cells. Quinone methide and cinnamaldehyde act in a synergistic manner to amplify oxidative stress, leading to preferential killing of cancer cells in vitro and in vivo. We therefore anticipate that QCA has promising potential as an anticancer therapeutic agent. 1 Department of Polymer Á Nano Science and Technology, Polymer Fusion Research Center, Chonbuk National University, Backje-daero 567, Jeonju 561-756, Korea. 2 Department of BIN Convergence Technology, Chonbuk National University, Backje-daero 567, Jeonju 561-756, Korea. Correspondence and requests for materials should be addressed to D.L. (email: [email protected]). NATURE COMMUNICATIONS | 6:6907 | DOI: 10.1038/ncomms7907 | www.nature.com/naturecommunications 1 & 2015 Macmillan Publishers Limited.
    [Show full text]
  • Cinnamaldehyde Induces Release of Cholecystokinin and Glucagon-Like
    animals Article Cinnamaldehyde Induces Release of Cholecystokinin and Glucagon-Like Peptide 1 by Interacting with Transient Receptor Potential Ankyrin 1 in a Porcine Ex-Vivo Intestinal Segment Model Elout Van Liefferinge 1,* , Maximiliano Müller 2, Noémie Van Noten 1 , Jeroen Degroote 1 , Shahram Niknafs 2, Eugeni Roura 2 and Joris Michiels 1 1 Laboratory for Animal Nutrition and Animal Product Quality (LANUPRO), Department of Animal Sciences and Aquatic Ecology, Ghent University, 9000 Ghent, Belgium; [email protected] (N.V.N.); [email protected] (J.D.); [email protected] (J.M.) 2 Centre for Nutrition and Food Sciences, Queensland Alliance for Agriculture and Food Innovation, The University of Queensland, St. Lucia, QLD 4072, Australia; [email protected] (M.M.); [email protected] (S.N.); [email protected] (E.R.) * Correspondence: [email protected] Simple Summary: The gut is able to “sense” nutrients and release gut hormones to regulate diges- tive processes. Accordingly, various gastrointestinal cell types possess transient receptor potential channels, cation channels involved in somatosensation, thermoregulation and the sensing of pungent and spicy substances. Recent research shows that both channels are expressed in enteroendocrine Citation: Van Liefferinge, E.; Müller, M.; Van Noten, N.; Degroote, J.; cell types responsible for the release of gut peptide hormones such as Cholecystokinin (CCK) and Niknafs, S.; Roura, E.; Michiels, J. Glucagon-like Peptide-1 (GLP-1). A large array of herbal compounds, used in pig nutrition mostly for Cinnamaldehyde Induces Release of their antibacterial and antioxidant properties, are able to activate these channels. Cinnamaldehyde, Cholecystokinin and Glucagon-Like occurring in the bark of cinnamon trees, acts as an agonist of Transient Receptor Potential Ankyrin 1 Peptide 1 by Interacting with (TRPA1)-channel.
    [Show full text]
  • Mechanisms of Synthesis of Purine Nucleotides in Heart Muscle Extracts
    Mechanisms of Synthesis of Purine Nucleotides in Heart Muscle Extracts David A. Goldthwait J Clin Invest. 1957;36(11):1572-1578. https://doi.org/10.1172/JCI103555. Research Article Find the latest version: https://jci.me/103555/pdf MECHANISMS OF SYNTHESIS OF PURINE NUCLEOTIDES IN HEART MUSCLE EXTRACTS1 BY DAVID A. GOLDTHWAIT2 (From the Departments of Biochemistry and Medicine, Western Reserve University, Cleveland, Ohio) (Submitted for publication February 18, 1957; accepted July 18, 1957) The key role of ATP, a purine nucleotide, in 4. Adenine or Hypoxanthine + PRPP -> AMP the conversion of chemical energy into mechanical or Inosinic Acid (IMP) + P-P. work by myocardial tissue is well established (1, The third mechanism of synthesis is through the 2). The requirement for purine nucleotides has phosphorylation of a purine nucleoside (8, 9): also been demonstrated in the multiple synthetic 5. Adenosine + ATP -, AMP + ADP. reactions which maintain all animal cells in the Several enzymatic mechanisms are known which steady state. Since the question immediately arises result in the degradation of purine nucleotides and whether the purine nucleotides are themselves in nucleosides. The deamination of adenylic acid is a steady state, in which their rates of synthesis well known (10): equal their rates of degradation, it seems reason- 6. AMP -* IMP + NH8. able to investigate first what mechanisms of syn- Non-specific phosphatases (11) as well as spe- thesis and degradation may be operative. cific 5'-nucleotidases (12) have been described At present, there are three known pathways for which result in dephosphorylation: the synthesis of purine nucleotides. The first is 7.
    [Show full text]
  • Calcium 5'-Ribonucleotides
    CALCIUM 5'-RIBONUCLEOTIDES Prepared at the 18th JECFA (1974), published in NMRS 54B (1975) and in FNP 52 (1992). Metals and arsenic specifications revised at the 57th JECFA (2001). An ADI ‘not specified’ was established at the 18th JECFA (1974). SYNONYMS Calcium ribonucleotides, INS No. 634 DEFINITION Chemical names (Mixture of) calcium inosine-5'-monophosphate and calcium guanosine-5'- monophosphate Chemical formula C10H11CaN4O8P · x H2O and C10H12CaN5O8P · x H2O Structural formula Calcium 5’-guanylate Calcium 5’-inosinate Assay Not less than 97% and not more than the equivalent of 102% of C10H11CaN4O8P and C10H12CaN5O8P, calculated on the anhydrous basis. The proportion of C10H11CaN4O8P or C10H12CaN5O8P to the sum of them is between 47% and 53%. DESCRIPTION Odourless, white or off-white crystals or powder FUNCTIONAL USES Flavour enhancer CHARACTERISTICS IDENTIFICATION Solubility (Vol. 4) Sparingly soluble in water Test for ribose (Vol. 4) Passes test Test for organic phosphate Passes test (Vol. 4) Test 5 ml of a 1 in 2,000 solution Test for inosinic acid To 2 ml of a 1 in 2,000 solution add 2 ml of 10% hydrochloric acid and 0.1 g of zinc powder, heat in a water bath for 10 min, and filter. Cool the filtrate in ice water, add 1 ml of a 3 in 1,000 sodium nitrite solution, shake well, and allow to stand for 10 min. Add 1 ml of a 1 in 200 ammonium sulfamate solution, shake well, and allow to stand for 5 min. Add 1 ml of a 1 in 500 N-(1- naphthyl)-ethylenediamine dihydrochloride solution.
    [Show full text]
  • The Xanthines (Theobromine and Aminophyllin)
    effect of this might conceivably escape detection in THE XANTHINES (THEOBROMINE AND individuals engaged in very heavy work. From this AMINOPHYLLINE) IN THE TREAT- point of view our subjects were particularly favorable for this since of as MENT OF CARDIAC PAIN study, most them, shown in the table, were not engaged in any occupation. HARRY M.D. GOLD, GLYCERYL TRINITRATE TEST NATHANIEL T. M.D. KWIT, Early in the course of the study it was believed AND desirable to HAROLD M.D. restrict the selection of patients to those OTTO, who could establish their qualifications for service in NEW YORK such a study as this by their ability to distinguish An endeavor was made in this study to secure evi- between the efficacy of glyceryl trinitrate taken under dence on the question of whether the xanthines relieve the tongue and a soluble placebo tablet taken in the cardiac pain. same manner for relief during attacks of pain. The SELECTION OF PATIENTS discovery of several patients who found the two equally effective those who had suffered an of The were 100 ambulant in attend- among attack subjects patients thrombosis and were to thoracic ance at the cardiac in whom the of coronary subject pain clinic, diagnosis on effort led us to abandon this restriction. arteriosclerotic heart disease with cardiac pain was made, in accordance with the nomenclature and criteria The results obtained in sixty patients in whom the the New York Heart Association.1 glyceryl trinitrate test was made are of some interest. adopted by These received trinitrate were selected from a total case load of patients glyceryl tablets, %0o They approxi- or cr 0.4 which were mately 700 patients, representing an average sample /4so grain (0.6 mg.), they of the cardiac clinic several racial directed to take under the tongue at the onset of an population, comprising attack of In of these of groups, both native and born.
    [Show full text]
  • Chocolate, Theobromine, Dogs, and Other Great Stuff
    Nancy Lowry, Professor of Chemistry, Hampshire College, Amherst, MA [email protected] Chocolate, Theobromine, Dogs, and Other Great Stuff. Chocolate is now considered a health food, according to many news reports. It provides a goodly dose of antioxidants, prolongs the lives of Dutch men, contains compounds that chemically echo tetrahydocannabinoid and encourage feelings of love, and it even “may halve the risk of dying,” according to a recent headline in the New Scientist. On the other hand, if chocolate is included in the diet in therapeutic doses, it will also most assuredly lead to obesity. Furthermore, the amounts of anandamide (the THC mimic) and phenylethylamine (the so-called “love” compound) are present in chocolate in very, very low amounts. And finally, we all have a 100% chance of dying at some time, so a headline that talks about cutting our chance of dying in half makes no sense. Nevertheless, chocolate is great stuff. It comes in many varieties. One end of the spectrum is bitter baking chocolate; adding sugar provides chocolate of various degrees of sweetness. Adding milk finally brings us to milk chocolate, which many people consider barely makes it over the line into chocolate. White chocolate is only cocoa butter fat, and really isn’t chocolate at all. Over 600 different molecules contribute to the taste of chocolate. Many people talk about the caffeine in chocolate, but there is relatively very little caffeine in chocolate; the compound that particularly characterizes chocolate is theobromine, a very close relative of caffeine. There is six to ten times more theobromine in chocolate than caffeine.
    [Show full text]
  • Effects of Allopurinol and Oxipurinol on Purine Synthesis in Cultured Human Cells
    Effects of allopurinol and oxipurinol on purine synthesis in cultured human cells William N. Kelley, James B. Wyngaarden J Clin Invest. 1970;49(3):602-609. https://doi.org/10.1172/JCI106271. Research Article In the present study we have examined the effects of allopurinol and oxipurinol on thed e novo synthesis of purines in cultured human fibroblasts. Allopurinol inhibits de novo purine synthesis in the absence of xanthine oxidase. Inhibition at lower concentrations of the drug requires the presence of hypoxanthine-guanine phosphoribosyltransferase as it does in vivo. Although this suggests that the inhibitory effect of allopurinol at least at the lower concentrations tested is a consequence of its conversion to the ribonucleotide form in human cells, the nucleotide derivative could not be demonstrated. Several possible indirect consequences of such a conversion were also sought. There was no evidence that allopurinol was further utilized in the synthesis of nucleic acids in these cultured human cells and no effect of either allopurinol or oxipurinol on the long-term survival of human cells in vitro could be demonstrated. At higher concentrations, both allopurinol and oxipurinol inhibit the early steps ofd e novo purine synthesis in the absence of either xanthine oxidase or hypoxanthine-guanine phosphoribosyltransferase. This indicates that at higher drug concentrations, inhibition is occurring by some mechanism other than those previously postulated. Find the latest version: https://jci.me/106271/pdf Effects of Allopurinol and Oxipurinol on Purine Synthesis in Cultured Human Cells WILLIAM N. KELLEY and JAMES B. WYNGAARDEN From the Division of Metabolic and Genetic Diseases, Departments of Medicine and Biochemistry, Duke University Medical Center, Durham, North Carolina 27706 A B S TR A C T In the present study we have examined the de novo synthesis of purines in many patients.
    [Show full text]
  • Trpa1) Activity by Cdk5
    MODULATION OF TRANSIENT RECEPTOR POTENTIAL CATION CHANNEL, SUBFAMILY A, MEMBER 1 (TRPA1) ACTIVITY BY CDK5 A dissertation submitted to Kent State University in partial fulfillment of the requirements for the degree of Doctor of Philosophy by Michael A. Sulak December 2011 Dissertation written by Michael A. Sulak B.S., Cleveland State University, 2002 Ph.D., Kent State University, 2011 Approved by _________________, Chair, Doctoral Dissertation Committee Dr. Derek S. Damron _________________, Member, Doctoral Dissertation Committee Dr. Robert V. Dorman _________________, Member, Doctoral Dissertation Committee Dr. Ernest J. Freeman _________________, Member, Doctoral Dissertation Committee Dr. Ian N. Bratz _________________, Graduate Faculty Representative Dr. Bansidhar Datta Accepted by _________________, Director, School of Biomedical Sciences Dr. Robert V. Dorman _________________, Dean, College of Arts and Sciences Dr. John R. D. Stalvey ii TABLE OF CONTENTS LIST OF FIGURES ............................................................................................... iv LIST OF TABLES ............................................................................................... vi DEDICATION ...................................................................................................... vii ACKNOWLEDGEMENTS .................................................................................. viii CHAPTER 1: Introduction .................................................................................. 1 Hypothesis and Project Rationale
    [Show full text]
  • Effect of Practical Timing of Dosage on Theophylline Blood Levels In
    Arch Dis Child: first published as 10.1136/adc.53.2.167 on 1 February 1978. Downloaded from Archives of Disease in Childhood, 1978, 53, 167-182 Short reports Effect of practical timing of dosage Methods on theophylline blood levels in For the period of the study, the children did not asthmatic children treated with receive tea, which contains theophylline. choline theophyllinate GroupA. These childrenwere given choline theophyll- The bronchodilator effect of theophylline has been inate in a dosage of as near as possible 8 mg/kg per known for over 50 years, but although it has been dose qds (mean 7 9 mg/kg, range 7-2-8 7 mg/kg), widely used both intravenously and rectally in the starting with half the dose on the first day to try and treatment ofacute asthma, its use as an oral broncho- minimise nausea. The doses were given at 0800 h, dilator has been limited by inadequate knowledge of 1300 h, 1700 h, and 2100 h, times considered suitable the correct dosage of the oral preparations. The for administration outside hospital. On the third day therapeutic level of theophylline is generally con- ofthe study serum levels were measured 2 hours after sidered to be between 10 and 20 ,ug/ml (Turner- each dose and before the 0800 h dose the following Warwick, 1957; Jenne et al., 1972), although sub- morning. optimal bronchodilation can be achieved with levels of 5 ,ug/ml or less (Maselli et al., 1970; Nicholson and Group B. These children were given cholinetheophyll- Chick, 1973). Serious toxicity with levels of less than inate in a dosage of as near as possible 10 mg/kg per copyright.
    [Show full text]
  • Chemical Tools for the Synthesis and Analysis of Glycans Thamrongsak Cheewawisuttichai [email protected]
    The University of Maine DigitalCommons@UMaine Electronic Theses and Dissertations Fogler Library 8-2019 Chemical Tools for the Synthesis and Analysis of Glycans Thamrongsak Cheewawisuttichai [email protected] Follow this and additional works at: https://digitalcommons.library.umaine.edu/etd Recommended Citation Cheewawisuttichai, Thamrongsak, "Chemical Tools for the Synthesis and Analysis of Glycans" (2019). Electronic Theses and Dissertations. 3058. https://digitalcommons.library.umaine.edu/etd/3058 This Open-Access Thesis is brought to you for free and open access by DigitalCommons@UMaine. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of DigitalCommons@UMaine. For more information, please contact [email protected]. CHEMICAL TOOLS FOR THE SYNTHESIS AND ANALYSIS OF GLYCANS By Thamrongsak Cheewawisuttichai B.S. Chulalongkorn University, 2012 A DISSERTATION Submitted in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy (in Chemistry) The Graduate School The University of Maine August 2019 Advisory Committee: Matthew Brichacek, Assistant Professor of Chemistry, Advisor Alice E. Bruce, Professor of Chemistry Barbara J.W. Cole, Professor of Chemistry Raymond C. Fort, Jr., Professor of Chemistry William M. Gramlich, Associate Professor of Chemistry Copyright 2019 Thamrongsak Cheewawisuttichai ii CHEMICAL TOOLS FOR THE SYNTHESIS AND ANALYSIS OF GLYCANS By Thamrongsak Cheewawisuttichai Dissertation Advisor: Dr. Matthew Brichacek An Abstract of the Dissertation Presented in Partial Fulfillment of the Requirements for the Degree of Doctor of Philosophy (in Chemistry) August 2019 Glycans can be found in every living organism from plants to bacteria and viruses to human. It has been known that glycans are involved in many biological processes such as structural roles, specific recognition with glycan-binding proteins, and host-pathogen recognitions.
    [Show full text]
  • Alternative Pathways of Glucose Metabolism II. Nucleotides from The
    Alternative Pathways of Glucose Metabolism II . Nucleotides from the Acid-soluble Fraction of Normal and Tumor Tissues and Studies on Nucleic Acid Synthesis in Tumors*t HANNS SCHMITZ4 VAN R. POTTER, ROBERT B. HTJRLBERT,@ AND DWAIN M. WHITE (McArdie Memovial Laboratory, the Medical School, University of Wisconain, Madison, WI..) The first paper (18) in this series on the alterna MATERIALS AND METHODS tive pathways of glucose metabolism established The present study has involved the measure the fact that radioactivity from glucose-i-C'4 was ment of the specific activities of the free 5' mono-, readily incorporated into the pentose moiety of the di-, and triphosphates of adenosine, guanosine, ribonucleic and desoxyribonucleic acids of Flexner cytidine, and uridine from the acid-soluble extract Jobling tumors in rats, and described the over-all of tumor tissue in relation to the specific activities distribution of radioactivity in the acid-soluble of the corresponding nucleotides that were oh and acid-insoluble fractions of tumor and liver tis tamed by chemical or enzymatic hydrolysis of the sue at various time periods. The acid-soluble frac nucleic acids from the same tissue samples, at tion of tissue contains an appreciable amount of specified time intervals after the injection of glu free nucleotides which are possible intermediary cose-1-C'4. The experimental plan corresponds compounds in the synthesis of the nucleic acids exactly to that described in the preceding paper; (6, 7, 8, 9, 13, 16). It was noted (18) that as the C'4 many of
    [Show full text]
  • Mechanism of Excessive Purine Biosynthesis in Hypoxanthine- Guanine Phosphoribosyltransferase Deficiency
    Mechanism of excessive purine biosynthesis in hypoxanthine- guanine phosphoribosyltransferase deficiency Leif B. Sorensen J Clin Invest. 1970;49(5):968-978. https://doi.org/10.1172/JCI106316. Research Article Certain gouty subjects with excessive de novo purine synthesis are deficient in hypoxanthineguanine phosphoribosyltransferase (HG-PRTase [EC 2.4.2.8]). The mechanism of accelerated uric acid formation in these patients was explored by measuring the incorporation of glycine-14C into various urinary purine bases of normal and enzyme-deficient subjects during treatment with the xanthine oxidase inhibitor, allopurinol. In the presence of normal HG-PRTase activity, allopurinol reduced purine biosynthesis as demonstrated by diminished excretion of total urinary purine or by reduction of glycine-14C incorporation into hypoxanthine, xanthine, and uric acid to less than one-half of control values. A boy with the Lesch-Nyhan syndrome was resistant to this effect of allopurinol while a patient with 12.5% of normal enzyme activity had an equivocal response. Three patients with normal HG-PRTase activity had a mean molar ratio of hypoxanthine to xanthine in the urine of 0.28, whereas two subjects who were deficient in HG-PRTase had reversal of this ratio (1.01 and 1.04). The patterns of 14C-labeling observed in HG-PRTase deficiency reflected the role of hypoxanthine as precursor of xanthine. The data indicate that excessive uric acid in HG-PRTase deficiency is derived from hypoxanthine which is insufficiently reutilized and, as a consequence thereof, catabolized inordinately to uric acid. The data provide evidence for cyclic interconversion of adenine and hypoxanthine derivatives. Cleavage of inosinic acid to hypoxanthine via inosine does […] Find the latest version: https://jci.me/106316/pdf Mechanism of Excessive Purine Biosynthesis in Hypoxanthine-Guanine Phosphoribosyltransferase Deficiency LEIF B.
    [Show full text]